The practical questions behind a serious engagement.
Clear answers on scope, timing, pricing, commercial relevance, public evidence and what Archoric does not claim.
Why discuss €200,000-plus opportunities and long sales cycles?
Because unclear decision support matters differently when one opportunity can involve months of evaluation, multiple departments and significant internal accountability. The figure describes the commercial context some Archoric prospects operate in. It is not a promise that Archoric will create, protect or progress a €200,000 opportunity.
Commercial boundary: Archoric does not guarantee revenue, conversion, sales-cycle reduction, pipeline protection or buyer behaviour.
Is this a website audit?
No. The website is one part of the public decision environment. Archoric reviews the evidence, explanations, routes and materials stakeholders can use before the demo, including public product, implementation, governance, security, evidence, outcome and customer resources.
What information does Archoric review?
The controlled scope may include product and solution pages, public evidence, studies, case material, security and governance resources, implementation explanations, documentation, FAQs, resource libraries, commercial entry routes and relevant downloadable assets.
What does the company receive?
The Assessment provides an executive decision condition, evidence-backed findings, stakeholder implications, tested-route records, prioritized recommendations and the traceability needed to understand how each conclusion was reached.
What is the difference between Assessment and Implementation?
The Assessment establishes what the public evidence supports, what remains unresolved and what should be addressed. Implementation converts approved findings into specific evidence routes, explanations, diagrams, content structures and public or gated decision-support assets.
Does Archoric need access to internal company information?
The initial Assessment can begin with public information alone. Internal context can later validate findings, resolve uncertainties, establish approved evidence boundaries and support implementation.
Can Archoric work with an early-stage company?
Yes, when the company has a sufficiently complex product, meaningful public claims and stakeholders who must evaluate implementation, governance, evidence, workflow or operational fit. Scope is determined during the initial review.
Is Archoric only for healthcare AI?
Healthcare AI and complex healthtech are the primary focus. Closely related high-stakes products may be considered when the decision involves several stakeholders and substantial evidence requirements.
How long does an engagement take?
It depends on the company, the controlled evidence scope, the number of routes and assets, stakeholder complexity and the agreed deliverables. Archoric provides a proposed schedule after the initial review and before the engagement begins.
How much does it cost?
Pricing is based on the scope and complexity of the engagement. Following an initial fit review, Archoric provides a clear proposal covering the agreed deliverables, timeline and fees. No work begins until the scope and commercial terms have been approved.
Can this work shorten a sales cycle or improve conversion?
Those outcomes are possible hypotheses to validate, not promises. Archoric can identify where the public decision environment leaves avoidable reconstruction, interpretation or coordination work. Actual outcomes depend on the product, market, sales process, implementation reality and buyer response.
Does an anonymized case mean the company was a client?
No. The public cases are independent method demonstrations based on public information. They do not imply a client relationship, approval, endorsement or commissioned engagement.
Where is Archoric based?
Archoric is legally established in Saint-Pierre, La Réunion, France, and works remotely with healthcare AI and complex healthtech companies internationally.
Bring the decision question. The scope can become clear after review.
The first conversation examines the product, the public evidence environment and the stakeholders involved.
Discuss the decision path